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Abstract
Environmental exposures are a potential trigger of chronic
pulmonary graft-versus-host disease (pGVHD) after successful
recovery from hematopoietic cell transplant (HCT). We
hypothesized that inhalations of LPS, a prototypic environmental
stimulus, trigger pGVHD via increased pulmonary recruitment of
donor-derived antigen-presenting cells (APCs) through the C-C
motif ligand 2 (CCL2)–C-Cmotif receptor 2 (CCR2) chemokine axis.
B10.BR(H2k) and C57BL/6(H2b) mice underwent allogeneic (Allo)
or syngeneic (Syn) HCT with wild-type (WT) C57BL/6, CCL22/2,
or CCR22/2 donors. After 4 weeks, recipient mice received daily
inhaled LPS for 5 days and were killed at multiple time points.
Allo mice exposed to repeated inhaled LPS developed prominent
lymphocytic bronchiolitis, similar to human pGVHD. The
increase in pulmonary T cells in Allo mice after LPS exposures
was accompanied by increased CCL2, CCR2, and Type-1
T-helper cytokines as well as by monocytes and monocyte-
derived dendritic cells (moDCs) compared with Syn and
nontransplanted controls. Using CCL22/2 donors leads to
a significant decrease in lungDCs but to onlymildly reduced CD4
T cells. Using CCR22/2 donors significantly reduces lung DCs
and moDCs but does not change T cells. CCL2 or CCR2
deficiency does not alter pGVHD pathology but increases airway
hyperreactivity and IL-5 or IL-13 cytokines. Our results show
that hematopoietic donor-derived CCL2 and CCR2 regulate
recruitment of APCs to the Allo lung after LPS exposure.
Although they do not alter pathologic pGVHD, their absence is
associatedwith increased airway hyperreactivity and IL-5 and IL-
13 cytokines. These results suggest that the APC changes that
result from CCL2–CCR2 blockade may have unexpected
effects on T cell differentiation and physiologic outcomes in
HCT.
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Clinical Relevance
Pulmonary graft-versus-host disease is a major source of
morbidity and mortality in recipients of hematopoietic cell
transplant. We show that during this disease process, C-C
motif ligand 2 (CCL2) and C-C motif receptor 2 (CCR2)
mediate recruitment of dendritic cells but do not prevent
lymphocytic inflammation. CCL2 and CCR2 deficiency
increase airway hyperreactivity, which argues for careful
assessment of physiologic side effects before future clinical
intervention upon this signaling axis.
Pulmonary complications after hematopoietic
cell transplant (HCT) are common,
poorly understood, understudied, and
difficult to treat, leading to calls for
further research in this area from the
National Institutes of Health, the
American Thoracic Society, and European
organizations (1–3). Despite advances
made in acute graft-versus-host disease
(GVHD) research (4), it remains unclear
why some patients recover well from
HCT and later develop chronic
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pulmonary GVHD (pGVHD). pGVHD
is characterized by lung T cell infiltration,
lymphocytic bronchiolitis, and later-
onset intraluminal airway fibrosis with
progressive airflow obstruction (1).
pGVHD differs from GVHD in other
organs in its time course, its pathology,
and its resistance to immunosuppressive
therapeutics, including anti–T cell
strategies. Evidence suggests that a key
reason for the unique characteristics
of pGVHD is the constant pulmonary
exposure to inflammatory stimuli not seen
by other organs. The resulting low-grade
lung inflammation appears to trigger or
exacerbate the development of pGVHD.
The specific mechanism by which this
occurs is not known, although increased
antigen presentation has been brought
forth as a potential mediating factor. Based
on studies of skin and gastrointestinal
GVHD, recipient antigen-presenting
cells (APCs) are thought to contribute
to acute GVHD by presenting alloantigen
to donor T cells, leading to subsequent
T cell expansion in target organs (4).
However, donor APCs and donor APC–T
cell interactions have not been studied in
the context of pGVHD.
Important recent advances in
pulmonary immunology have taught us that
there are multiple subsets of APCs in the
lung, including subspecialized dendritic cells
(DCs), which are highly efficient at antigen
presentation. These DCs are not resident
to the lung but rather are monocyte derived
and recruited to the lung and pulmonary
lymph nodes via chemokine binding to
their C-C motif receptor 2 (CCR2) (5, 6).
Although several chemokines bind
CCR2 and cause lymph node monocyte
recruitment, monocyte chemoattractant
protein-1 (MCP-1)/C-C motif ligand 2
(CCL2) appears to be the primary
chemokine responsible for tissue monocyte
recruitment. The recruited CCR2-positive
monocyte-derived DCs (moDCs) have been
shown to be very effective T cell stimulators
and potentiators of Type 1 T-helper (Th1)
adaptive responses (6).
Although CCL2 and CCR2 appear
to regulate acute GVHD in animal models
(7–9), their role in chronic GVHD has
not been addressed. To study the features
of chronic pGVHD, we have established
a novel model system in which mice
recover from allogeneic HCT (Allo mice)
and then are challenged with repeated
exposures to inhaled LPS (iLPS) for
1 week, replicating clinically relevant
workplace or domestic exposures. Allo
mice challenged with iLPS develop
prominent lymphocytic bronchiolitis,
similar to human pGVHD (10, 11). In
this present study, we demonstrate that
the lungs of Allo mice after iLPS have
markedly elevated CCL2 levels and
exaggerated recruitment of donor moDCs,
as compared with syngeneic controls. We
further show that HCT using CCL2- or
CCR2-deficient donors decreases the DC
influx without preventing the development
of lymphocytic bronchiolitis at a cellular or
histologic level. Instead, donor CCL2
or CCR2 deficiency negatively affects
pulmonary physiology with augmented
airway hyperreactivity (AHR) and an
increase in IL-5 and IL-13 cytokines.
Materials and Methods
Murine HCT and LPS Exposures
Male, 8- to 10-week-old, C57Bl/6(H2b) or
B10.BR(H2k) recipient mice underwent
HCT with 4 3 106 bone marrow cells and
1 3 106 splenocytes (10) from C57Bl/6
wild-type (WT), CCL22/2, or CCR22/2
donors (6). Four weeks after HCT, mice
were exposed to 4.5 mg/m3 LPS aerosol
(12, 13) for 2.5 h/d for five consecutive
days. Mice were killed without LPS
exposure, at 4 hours after 1 LPS exposure,
or at 4 hours, 24 hours, 72 hours, or
7 days after the fifth LPS exposure.
Further details are provided in the
online supplement.
Bronchoalveolar Lavage and Lung
Tissue Analysis
After performing bronchoalveloar lavage
(BAL), the smallest right accessory lung lobe
was used for RNA analysis, the remaining
right lung for flow cytometry, and the left lung
for pathology. Cytokine analysis was
performed on the BAL supernatant using
specific CCL2, IL-4, IL-5, and IL-13 ELISA
kits (R&D Systems, Minneapolis, MN) and
mouse 23-plex and 9-plex cytokine assays
that included detection of IFN-g, IL-12p40,
and IL-12p70 (Bio-Rad Laboratories,
Hercules, CA). RNA transcripts were
measured using Taqman probe-and-primer
combinations for the Th1-specific
transcription factor T-box-expressed-in-
T cells (T-bet), CCL2, CCR2, IL-12b, CD103,
and endogenous b-actin. Further details are
provided in the online supplement.
Flow Cytometry




CD4 (BioLegend, San Diego, CA). The




(Ly6G/Ly6C) (BD Biosciences, San Jose,
CA), APC-conjugated anti-mouse
CD11c (eBioscience, San Diego, CA),
PE-Cy7–conjugated anti-mouse CD11b,
and PerCP-Cy5.5–conjugated anti-mouse
CD45 (Biolegend). The intracellular
cytokine-staining panel included FITC-




mouse IL-5, and APC-conjugated
anti-mouse IFN-g (eBioscience). Flow
cytometry analysis was performed
using FlowJo software (Tree Star Inc.,
Ashland, OR). A singlet gate was used
to exclude cell aggregates, followed by
an all-cell gate to exclude small debris
and dead cells and a CD451 cell gate
to define all white blood cells. Myeloid
cell gating was done based on previously
published studies (5, 6) defining
inflammatory monocytes as Ly6G2CD11c2
MHCII2CD11b1SSCsmallGr11 cells, DCs as
Ly6G2CD11c1MHCIIhigh, and moDCs as
Ly6G2CD11c1MHCIIhighCD11b1Gr11.
Cell percentages are expressed as percentage
of all cells and converted to absolute numbers
by multiplying by live-cell counts.
Airway Physiology Measurements
Lung physiology measurements were
performed 72 hours after LPS exposures
using the flexiVent mechanical ventilator
and data acquisition system (SCIREQ,
Montreal, Quebec, Canada). Further details
are provided in the online supplement.
DC and T Cell Coculture
T cells from naive B10.BRmice were cocultured
with lung DCs from nontransplanted (NT)
LPS-exposed C57BL/6 WT, CCL22/2, or
CCR22/2 mice. After 5 days of coculture, cells
were stimulated, and intracellular IL-5 was
measured by flow cytometry. Further details
are provided in the online supplement.
Statistical Analysis
Data are expressed as means 6 SEM.
Individual comparisons between groups at
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each time point were performed using
a Student’s t test. Curves for airway
resistance and dynamic compliance
in response to increasing doses of
methacholine were compared using a two-
way ANOVA for repeated measures
analysis. Throughout the graphs, star (*)
and plus sign (1) indicate a P value
of , 0.05. For knockout experiments, (*)
refers to the comparison between CCR22/2
and WT, and (1) refers to the comparison
between CCL22/2 and WT.
Results
iLPS Potentiates pGVHD in Mice after
Allogeneic HCT
Mice that recover from allogeneic HCT
(Allo) or syngeneic HCT (Syn) have only
minimal pulmonary pathology at baseline.
The pulmonary response of Allo, Syn,
and NT mice to subacute exposures to
aerosolized LPS was studied at 4 hours after
one LPS exposure and at 4 hours, 24 hours,
72 hours, and 7 days after five daily LPS
exposures. The BAL flow cytometric
analysis is shown and parallels data from
lung tissue (lung tissue data not shown). In
response to subacute exposures to daily
aerosolized LPS, Allo mice demonstrate
a significantly stronger lymphocytic
inflammatory response compared with
Syn and NTmice at all time points and as far
out as 1 week after the LPS exposures
(Figure 1). This inflammatory response in
Allo mice is consistent with features of
pGVHD, with increased numbers of
pulmonary CD4 and CD8 T cells (Figures
1A–1C). Elevated transcript levels of
T-bet (Figure 1D) and a strong IFN-g
production (Figures 1E and 1F) in the
lungs are also seen after LPS exposures,
suggesting Th1 polarization. However,
IFN-g levels drop rapidly when LPS
administration is stopped on Day 6, despite
increased T cell accumulation. This is
likely due to the fact that, whereas acute
LPS exposure stimulates robust IL-12
production, continued exposure leads to
APC exhaustion and the decreased
production of IL-12 (14). In addition,
other inflammatory mediators induced
by LPS, such as NOS2 (15), which we
also find to be up-regulated in lungs of
Allo mice exposed to LPS (data not
shown), have been demonstrated to
inhibit T cell IFN-g production. The
associated pathologic findings in Allo mice
exposed to LPS include pulmonary
perivascular mononuclear infiltrates and
lymphocytic bronchiolitis (Figure 1G).
iLPS Leads to Expansion of
Pulmonary Inflammatory Monocytes
and moDCs in Mice after Allogeneic
HCT with Up-regulation of CCL2,
CCR2, and IL-12
Detailed flow cytometric analysis of APC
subsets in the lungs of Allo mice reveals
an increased presence of inflammatory
APCs compared with Syn and NT mice
(Figures 2A–2C). At this time point,
. 95% of lung myeloid cells in Allo mice
are donor derived (see Figure E1 in the
online supplement). CD11b1CD11c2
inflammatory monocytes that express
high levels of Gr1 are significantly
more abundant after LPS in the lungs
of Allo mice (Figures 2B and 2D).
CD11c1MHCII1High DCs are also present
in high numbers (Figures 2A and 2E), and
moDCs that coexpress CD11b and Gr1
(Figures 2C and 2G) are increased
compared with controls. Total CD11b1
DCs (Figures 2C and 2F), a population of
DCs that is thought to result from the loss
of the Gr1 surface markers by moDCs (5),
is also increased after Allo HCT. Based on
recent publications showing that CCR2-
expressing inflammatory monocytes get
recruited into the lung via a CCL2
chemokine gradient and give rise to moDCs
(6), we investigated this signaling pathway
in our model. Increased levels of CCL2
transcript are present in the lung tissue
(Figure 3A), and protein is elevated in the
BAL (Figure 3B) of Allo mice after LPS
exposure when compared with Syn and
NT controls. Furthermore, the CCR2
transcript is increased in lungs of Allo mice
72 hours after LPS exposure (Figure 3C).
Additionally, the main cytokine produced
by Th1-polarizing moDCs, IL-12, is found
in significantly higher levels in Allo mice
after LPS exposure compared with Syn and
NT controls (Figures 3D–3F). Consistent
with our IFN-g data, IL-12 production
falls off rapidly when LPS administration
is stopped despite increasing accumulation
of moDCs, suggesting that APC exhaustion
or inhibition by other inflammatory
mediators reduces IL-12 expression in
the absence of its being driven by LPS
exposures (14). Overall, these data indicate
that subacute exposures to iLPS in mice
after allogeneic HCT lead to exaggerated
pulmonary recruitment of inflammatory
monocytes. These monocytes have
previously been shown to express CCR2
and to differentiate into moDCs that confer
a Th1-polarizing phenotype to the adaptive
T cell response (6).
In Allo Mice Exposed to LPS, Absence
of CCL2 or CCR2 on Donor
Hematopoietic Cells Leads to
Decreased Detection of Pulmonary
CCL2 and CCR2, Respectively
Based on the above data, we postulated that
inflammatory moDCs recruited to the lung
during environmental exposures in Allo
mice lead to increased T cell activation,
recruitment, and expansion, with
consequent exacerbation of pGVHD
pathology and physiology. To evaluate
whether CCL2 and/or CCR2 mediate
recruitment of moDCs and generation of
pGVHD in mice after HCT and iLPS, we
performed experiments using donor mice
deficient in CCL2 or CCR2. Absence of
the CCL2 gene in donor mice leads to
a significant decrease in CCL2 protein in
the BAL of Allo mice exposed to iLPS
(Figure 4A) with no change in the lung
tissue CCL2 or CCR2 transcripts (Figures
4B and 4C). This suggests that a significant
component of the CCL2 produced in the
lungs of Allo mice after LPS exposure is
produced by airspace donor-derived
hematopoietic cells (e.g., macrophages)
(Figure 4A). However, other structural
lung cells also contribute to CCL2
production, which is thus not completely
abrogated in these experiments (Figures
4A and 4B). Allo mice transplanted
with donor cells deficient in CCR2 have
significantly decreased CCR2 transcript
levels in the lung tissue (Figure 4C)
with an increase in CCL2 protein levels
in the BAL (Figure 4A), consistent
with compensatory changes previously
described in CCR2-deficient mice
(16–18).
Absence of CCL2 or CCR2 on Donor
Hematopoietic Cells Leads to a
Decrease in Pulmonary DCs in Allo
Mice after LPS Exposure
LPS-exposed Allo mice transplanted with
CCL2- or CCR2-deficient donor cells have
no significant reduction in inflammatory
monocytes at the time points studied
(Figure 5A) but display reduced expansion
of DCs (Figure 5B) and total CD11b1 DCs
(Figure 5C) compared with the WT
group. This finding suggests that
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inflammatory monocyte recruitment can
be mediated by CCL2 produced by
recipient cells or by CCR2 ligands other
than CCL2 but that donor-derived CCL2
contributes to DC expansion. In
contrast, LPS-exposed Allo mice
transplanted with CCR2-deficient donor
cells display reductions in all DC subsets
(Figures 5B–5D), consistent with
a requirement for CCR2 on donor
cells for DC localization and/or
differentiation.
Figure 1. Inhaled LPS potentiates pulmonary graft-versus-host disease (pGVHD) in mice after allogeneic hematopoietic cell transplant (HCT). Mice received an
allogeneic HCT (Allo), syngeneic HCT (Syn), or no HCT (nontransplanted [NT]). Allo, Syn, and NT mice underwent daily exposures to aerosolized LPS for 5 days. The
LPS exposures were staggered to kill mice without LPS exposures, at 4 hours after one LPS exposure, and at 4 hours, 24 hours, 72 hours, and 7 days after
five daily LPS exposures. (A–C) T cells were measured in the bronchoalveolar lavage (BAL) by flow cytometry. LPS exposures led to an increase in BAL total CD31
T cells (A), CD41 T cells (B), and CD81 T cells (C) in Allo mice as compared with Syn or NT mice. (D and E) the Th1-specific transcription factor T-box-expressed-in-
T cells (T-bet) and IFN-g mRNA transcripts, measured in whole lung tissue, are elevated in the lungs of Allo mice as compared with Syn or NT mice. (F) IFN-g
BAL protein levels, as measured by ELISA, are elevated in Allo mice compared with Syn and NT controls. (G) Representative lung histology images show lymphocytic
bronchiolitis and perivascular lymphocytic infiltrates in Allo mice 4 hours, 72 hours, and 7 days after 5 days of LPS exposures (hematoxylin and eosin; original
magnification: 3100). Syn mice at these time points have evidence of much milder lymphocytic inflammation. Allo and Syn mice not exposed to LPS have minimal
lung inflammation on histology. Quantitative data represent the average 6 SEM. *P , 0.05. Data have been replicated in three independent experiments.
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Figure 2. Allogeneically transplanted mice exposed to inhaled LPS have increased pulmonary inflammatory monocytes and dendritic cells
(DCs) compared with syngeneic or nontransplanted mice. Mice underwent an allogeneic HCT (Allo), syngeneic HCT (Syn), or no HCT
(nontransplanted or NT) with subsequent daily exposures to aerosolized LPS for 5 days. Mice were killed without LPS exposure, at 4 hours after
one LPS exposure, and at 4 hours, 24 hours, 72 hours, and 7 days after five daily LPS exposures. (A–C) Representative BAL cell flow cytometry
plots are shown for Allo and Syn mice without LPS and 4 hours after five daily LPS exposures. (A) CD451Ly6G2 nonneutrophil leukocytes
are shown. The highest percentage of CD11c1MHCIIHigh DCs is found in the Allo LPS-exposed mice as compared with Allo LPS-unexposed and
Syn mice. (B) Among CD11c2MHCII2 cells, the CD11b1 monocytes have the highest expression of Gr1 in the Allo LPS-exposed group.
(C) When evaluating the Gr1 and CD11b expression on the DC population, the Allo LPS-exposed mice have the highest percentage of CD11b1
and of Gr11CD11b1 double-positive DCs. (D–G) Total numbers of BAL monocyte and DC subsets are graphed. Allo mice exposed to LPS
have higher absolute numbers of inflammatory Gr11CD11b1 monocytes (D), DCs (E), total CD11b1 DC (F), and Gr11CD11b1 monocyte-derived
DCs (moDCs) (G) as compared with Syn and NT controls. Data represent the average 6 SEM. *P , 0.05. Data have been replicated in two
independent experiments.
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Absence of CCL2 but Not CCR2 on
Donor Hematopoietic Cells Leads to
a Mild T Cell Decrease, but Neither
Gene Deficiency Abrogates pGVHD
Pathology or IFN-g Production
Allo mice transplanted with CCL2-deficient
donors have a significant reduction in CD4
T cells at 4 hours after five LPS exposures,
but this decrease is no longer evident at
72 hours after LPS exposure (Figures 6A
and 6B). There is no significant difference
in CD8 T cells in Allo mice transplanted
with CCL2-deficient donors (Figure 6C).
Allo mice transplanted with CCR2-deficient
donors have no change in T cells at any
time point (Figures 6A–6C). Neither CCL2
deficiency nor CCR2 deficiency in donor
cells changes IFN-g levels in the BAL
(Figure 6D) or the overall pGVHD
pathology at 4 and 72 hours after 5 days of
LPS exposure (Figure 6E). In summary,
neither CCL2 nor CCR2 deficiency
abrogates pGVHD, although CCL2
deficiency is associated with a mild CD4
T cell reduction at an early time point.
Absence of CCL2 or CCR2 on Donor
Hematopoietic Cells Increases AHR in
Allo Mice Exposed to LPS with
Up-regulation of IL-13 or IL-5 and
Increased Th2-Promoting DCs
Although the overall pathology is not
different in the knockout groups, we
postulated that CCR2 or CCL2 deficiency
would improve lung physiology, and we
therefore evaluated airway resistance and
compliance in our model with CCR2- and
CCL2-deficient donors. Contrary to our
expectations, 72 hours after LPS exposures,
Allo mice transplanted with CCL2- or
CCR2-deficient donors show higher airway
resistance (Figure 7A) and lower airway
dynamic compliance (Figure 7B) in
response to methacholine, as compared
with WT controls. Static lung compliance is
not significantly different between the
groups (data not shown), suggesting that
the decrease in dynamic compliance is due
to airway disease and not due to lung
parenchymal tissue changes. These
physiologic changes suggest a process of
airway remodeling that occurs in the setting
of donor CCL2 or CCR2 deficiency,
although no increase in airway fibrosis
was seen on pathologic analysis and no
change in collagen levels was observed
(data not shown).
To better understand the mechanisms
of these AHR responses, we wondered
whether cytokines that have been ascribed to
Th2 differentiation and involved in AHR
in asthma models might be implicated in
our findings. Indeed, Allo mice transplanted
with CCL2-deficient donors have increased
IL-13 in their BAL after LPS exposure
(Figure 7C), whereas Allo mice transplanted
with CCR2-deficient donors have increased
IL-5 levels (Figure 7D). IL-4 levels are not
different between the groups (data not
shown).
We then assessed whether CCL2 or
CCR2 deficiency in our studies may change
the DC populations toward an increase in
Th2-potentiating DCs. CD1031 DCs, which
are for the most part all CD11b2, have been
studied in models of allergic asthma and
have been found to have a strong capacity
Figure 3. Allogeneically transplanted mice exposed to inhaled LPS have increased pulmonary C-C
motif ligand 2 (CCL2), C-C motif receptor 2 (CCR2), and IL-12. Mice underwent an allogeneic HCT (Allo),
syngeneic HCT (Syn), or no HCT (NT) with subsequent daily exposures to aerosolized LPS for 5 days.
Mice were killed without LPS exposures, at 4 hours after one LPS exposure, and at 4 hours, 24 hours,
72 hours, and 7 days after five daily LPS exposures. Whole lung tissue mRNA transcript and BAL protein
levels are shown. Allo mice exposed to LPS have increased CCL2 transcript in the lung tissue (A) and
increased CCL2 protein in the BAL (B), compared with Syn and NT controls. Allo mice also have increased
CCR2 (C) and IL-12b transcripts (D) in the lung tissue and increased IL-12 protein in the BAL (both the
homodimer p40 [E ] and heterodimer p70 [F ]). Data represent the average 6 SEM. *P , 0.05. Data have
been replicated in two independent experiments.
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to polarize CD4 T cells toward the Th2
phenotype (19). We therefore assessed the
presence of CD11b2 DCs in Allo mice
transplanted with CCL2- or CCR2-deficient
donors, 72 hours after 5 days of LPS
exposures. CD11b2 DCs constitute a higher
proportion of all DCs (Figure 7E), with
a higher CD11b2 to CD11b1 DC ratio
(Figure 7F), in the CCR2-deficient group
compared with WT. Additionally, the
CD103 transcript is elevated in the CCL2-
deficient group compared with WT
(Figure 7G). This suggests that CD1031/
CD11b2 Th2-promoting DCs are relatively
more abundant in LPS-exposed Allo mice
transplanted with CCL2- or CCR2-deficient
donor cells compared with WT controls.
DCs from LPS-Exposed Lungs of
CCR22/2 Mice Change T Cell
Differentiation toward Increased
IL-5 Production
We sought to evaluate whether DC
populations that expand in response to LPS
in the setting of CCL2 or CCR2 deficiency
differentially stimulate allogeneic T cells.
DCs were isolated from WT, CCL2-
deficient, and CCR2-deficient mice 24 hours
after five daily LPS exposures. Compared
with WT controls, the lungs from CCR22/2
and CCL22/2 mice have lower proportions
of Gr11CD11b1 moDCs and CCR22/2
mice also have slightly lower Gr12CD11b1
DCs (Figure E2). More pertinently, the
percentage of CD11b2 DCs is markedly
higher in CCR22/2 and only slightly
elevated in CCL22/2 as compared with WT
lungs (Figure E2). Allogeneic T cells
cocultured with DCs from CCR22/2 mice
produce more IL-5 compared with
cocultures with DCs from WT mice
(Figures 7H and 7I). This suggests that
CCR2 deficiency leads to a shift toward
populations of CD11b2 DCs that
preferentially promote proliferation of
IL-5–expressing T cells. There is a trend
toward increased IL-51 CD4 and IL-51
CD8 T cells, but the differences are not
statistically significant, likely due to low
T cell numbers. Therefore, we cannot
comment specifically on the effect of
CD11b2 DCs on Th2 versus Tc2 cells,
although it is plausible that they have
effects on both. The DCs from CCL22/2
mice did not increase IL-5 production by
T cells (Figures 7H and 7I), presumably due
to lower proportions of CD11b2 DCs
compared with the CCR22/2 mice.
Additionally, production of IFN-g by
T cells is not different between the groups
(data not shown), which is likely due to
the large number of Th1-polarizing
CD11b1 DCs present regardless of CCR2
or CCL2 deficiency. Overall, these results
show that decreasing recruitment of
CCR21 cells to the lung results in
a pulmonary DC population that has
a higher propensity to stimulate IL-5
production by T cells.
Discussion
In this investigation, we show that subacute,
environmentally triggered pGVHD is
accompanied by up-regulation of the
CCL2–CCR2 chemokine axis and
expansion of pulmonary moDCs. However,
the absence of CCR2 or CCL2 in donor-
derived hematopoietic cells does not
prevent pGVHD despite a decrease in
pulmonary DCs. Instead, CCR2 or CCL2
deficiency worsens AHR with up-regulation
of IL-13 or IL-5.
We demonstrate that CCR2 mediates
pulmonary recruitment of donor moDCs
to the lungs of Allo mice in response to
iLPS. This is consistent with prior
non–transplant-related studies showing
that CCR2 is important for recruitment
of moDCs to inflamed lungs after influenza
infection (5, 6). Nevertheless, ours is the
first report of this phenomenon after HCT
at a delayed time point where the majority
of pulmonary APCs are donor derived.
Our findings stand in contrast to acute
GVHD, where tissue host APCs interact
with donor T cells (4). A study of post-HCT
idiopathic pneumonia syndrome, which
is a form acute pGVHD, showed that CCR2
expression on host cells did not affect
pulmonary APC numbers or development
of lung disease (7).
Donor CCL2 deficiency leads to
reduced pulmonary DCs at an early post-
iLPS time point but does so to a lesser degree
compared with CCR2 deficiency in our
experiments. Previous studies have reported
that the source of CCL2 is the hematopoietic
compartment in other transplant settings
(20–22). However, our data show that the
use of CCL2-deficient HCT donors leads
to only a partial reduction in the overall
pulmonary CCL2 levels, which likely
Figure 4. Allogeneic HCT mice transplanted with CCL22/2 or CCR22/2 donors have reduced pulmonary CCL2 and CCR2, respectively. Mice underwent
an allogeneic HCT using wild-type (WT), CCL22/2, or CCR22/2 donors and were killed without LPS exposure and at 4 and 72 hours after 5 days of daily
LPS exposures. Allo mice transplanted with CCL22/2 donors have reduced CCL2 protein in their BAL (A) but have unchanged CCL2 (B) and CCR2
transcripts (C) in the lung tissue. Allo mice transplanted with CCR22/2 donors have elevated CCL2 protein in their BAL (A), unchanged CCL2 transcripts in
the lung tissue (B), and reduced CCR2 transcript in the lung (C). Data represent the average 6 SEM and have been replicated in two independent
experiments. 1P , 0.05 comparing CCL22/2 group with WT. *P , 0.05 comparing CCR22/2 group with WT.
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accounts for the reduced effect on DC
recruitment.
Contrary to our expectations, reduction
of the post-LPS influx of DCs does not
translate into ameliorated pGVHD as
measured by lymphocytic inflammation and
AHR. In fact, the T cell expansion appears to
be independent of DCs and moDCs. This
may explain the disconnect between the
early peak (4 h after first LPS exposure) in
IFN-g and IL-12 proteins and the later peak
in DC and moDC numbers (4–72 h after
five LPS exposures). It is possible that other
cell populations, such as macrophages
or neutrophils, contribute to cytokine
production. Our analyses have not shown
differences in macrophage or neutrophil
numbers between the groups studied, but
cell-specific cytokine production and cell
function will need to be given additional
attention in future experiments to better
elucidate their roles.
We cannot exclude the possibility that
T cell stimulation and proliferation occur in
lymphoid organs and not in the lung, which
could represent another explanation as to
why reduced DC numbers in the lung do not
equate to reduced T cell numbers. However,
we have not been able to adequately study
lymph nodes in our Allo mice because all
lymphoid structures are atrophied and
extremely difficult to identify due to low-
grade chronic GVHD, a phenomenon that
has been well described in the literature (23).
Our limited analysis of lymph node cell
populations have not shown any major
differences in DCs or T cells between WT,
CCR22/2, and CCL22/2 groups (data not
shown). We have assessed spleen cell
populations and also found low cell
numbers in all Allo spleens and no
significant changes between the WT,
CCR22/2, and CCL22/2 groups studied
(data not shown). Given the lymphoid
organ atrophy, we believe that, in the
context of pGVHD, DC–T cell interactions
may occur in the lung itself. This would be
consistent with findings from the mouse
model of orthotopic lung transplantation,
where rejection occurs in the absence of
secondary lymphoid structures and where
DC–T cell interactions have been identified
within the lung allograft (16, 24).
Our body of data indicates that LPS-
mediated T cell expansion may occur
independent of APC stimulation. In fact, the
CCL2 chemokine may be exerting its effect
directly on T cell receptors. This would
explain the small reduction in pulmonary
CD4 T cells in the Allo group transplanted
with CCL2-deficient donors. In the
experiments using CCR2-deficient donors,
we demonstrate a concurrent compensatory
increase in CCL2, which suggests a
potential CCL2-mediated, CCR2-independent
mechanism of T cell recruitment proposed in
other publications (25–27). Compensatory
CCL2 up-regulation does not appear to take
place in acute GVHD based on the literature,
perhaps due to the shorter timeline of the
experiments or their lack of environmental
stimuli. This would explain why donor
CCR2 deficiency reduced pulmonary T cell
recruitment to the lung in a model of acute
idiopathic pneumonia syndrome (8) and
why CCR2 was found to mediate systemic
disease in a model of acute CD8-induced
GVHD (9).
In addition to not ameliorating
pGVHD pathology, donor CCR2 and CCL2
deficiency in our experiments led to
a modest increase in AHR in allogeneic
HCT mice exposed to iLPS. This increase in
AHR correlates with an up-regulation of
IL-13 in the CCL2-deficient group and IL-5
in the CCR2-deficient group. Given the
published literature on Th2 cytokines, such
as IL-13 and IL-5, mediating AHR in asthma
models (28), we further investigated
whether CCR2 and CCL2 deficiency in our
experiments promote a Th2 environment.
We found an increase in the proportion
of CD11b2 DCs in the setting of CCR2
deficiency and elevated CD103 transcript
levels in CCL2 deficiency. This suggests that
Allo mice transplanted with CCR22/2 or
CCL22/2 may have a relative increase in
Figure 5. Allogeneic HCT mice transplanted with CCL22/2 or CCR22/2 donors have reduced
pulmonary DCs. Mice underwent an allogeneic HCT using WT, CCL22/2, or CCR22/2 donors and
were killed without LPS and at 4 and 72 hours after 5 days of daily LPS exposures. BAL cells were
analyzed via flow cytometry. (A) Allo mice transplanted with either CCL22/2 or CCR22/2 donors
have only a trend toward reduced inflammatory monocytes in their BAL. (B and C) Allo mice
transplanted with CCL22/2 donors have a significant reduction in overall DC (B) and CD11b1 DC (C),
but not in moDC numbers (C). (B–D) Allo mice transplanted with CCR22/2 donors have a significant
reduction in the overall DC, CD11b1 DC, and moDC numbers in their BAL. Data represent the
average 6 SEM and have been replicated in two independent experiments. 1P , 0.05 comparing
CCL22/2 group with WT. *P , 0.05 comparing CCR22/2 group with WT.
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pulmonary CD11b2/CD1031 DCs,
which have been described in the
literature as potentiators of Th2
differentiation (19). We also showed that
nontransplanted CCR22/2 mice after LPS
exposure have a higher proportion of lung
CD11b2 DCs, and their DCs have
a stronger propensity to stimulate in vitro
IL-5 production by allogeneic T cells
compared with WT controls. In contrast,
DCs from CCL22/2 LPS-exposed mice
have a minimal increase in the proportion
of CD11b2 DCs, and these DCs do not
change IL-5 production by allogeneic
T cells in vitro. These in vitro data are
consistent with our in vivo findings that
CCR2 deficiency has a stronger effect,
compared with CCL2 deficiency, on
decreasing DCs and moDCs, increasing
the proportion of CD11b2 DCs, and
augmenting IL-5. In light of this, it is
interesting that CCL2 deficiency has
a similar effect on AHR as CCR2, and we
suspect that this is due to the contribution
of other mechanisms that we have not
explored in this study, such as direct effects
of CCL2 on T cell recruitment and
polarization. Additionally, although we
think that a plausible mechanism of
increased AHR in the setting of donor
CCR2 or CCL2 deficiency includes relative
increases in DCs that polarize T cells
toward IL-5 and IL-13 production, we
cannot exclude the possibility that these
cytokines are produced by other cells
in vivo.
The increase in AHR and IL-5 with
CCR2-deficient donors is consistent with
several studies showing that CCR2
deficiency increases AHR in nontransplant
settings. One study focused on an OVA
allergy model using multiple repeat
exposures to aerosolized OVA (29), and the
other used an aspergillus sensitization and
live conidia exposure model (30). Both
of these studies showed up-regulation of
the pulmonary IL-5 cytokine in the CCR2-
knockout mice. Other studies in the
Figure 6. Allogeneic HCT mice transplanted with CCL22/2 but not CCR22/2 donors have a mild reduction in CD3 and CD4 T cells, although neither gene
deficiency changes CD8 T cells, IFN-g, or pGVHD pathology. Mice underwent an allogeneic HCT using WT, CCL22/2, or CCR22/2 donors and were
killed without LPS exposure and at 4 and 72 hours after 5 days of daily LPS exposures. BAL cells were analyzed via flow cytometry and pulmonary
histology was assessed. (A and B) Allo mice transplanted with CCL22/2 but not CCR22/2 donors have a reduction in CD3 (A) and CD4 T cells (B)
at 4 hours after 5 days of LPS exposure. (C and D) Neither CCL2 nor CCR2 deficiency leads to CD8 T cell reduction (C) or decrease in IFN-g protein (D)
in the BAL. (E) Representative lung histology images are shown (hematoxylin and eosin; original magnification: 3100). There is no significant change
in pGVHD pathology, including perivascular and peribronchiolar lymphocytic infiltrates, in Allo mice transplanted with CCL22/2 or CCR22/2 donors.
Quantitative data represent the average 6 SEM and have been replicated in two independent experiments. 1P , 0.05 comparing CCL22/2 group
with WT. *P , 0.05 comparing CCR22/2 group with WT.
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Figure 7. Allogeneic HCT mice transplanted with CCL22/2 or CCR22/2 donors have increased AHR, IL-13 or IL-5 cytokines, and Th2-promoting DCs after LPS
exposures. Mice underwent an allogeneic HCT using WT, CCL22/2, or CCR22/2 donors and were killed without LPS exposure and at 4 and 72 hours after
5 days of daily LPS exposures. Airway resistance and compliance in response to methacholine were measured in vivo before mice were killed, 72 hours
after LPS exposures. (A) In Allo mice exposed to LPS, donor CCL2 or CCR2 deficiency leads to increased dynamic airway resistance in response to methacholine
(P , 0.05 when comparing WT and CCR22/2). (B) In Allo mice, donor CCR2 or CCL2 deficiency leads to decreased dynamic lung compliance in response to
methacholine (P, 0.05 when comparingWT and CCL22/2). (C) Allo mice transplanted with CCL22/2 donors have increased IL-13 protein in their BAL at 72 hours after
LPS exposures. (D) Mice transplanted with CCR22/2 donors have increased IL-5 protein in their BAL at 4 hours after LPS exposures. (E and F ) Allo mice transplanted
with CCR22/2 donors have an elevated proportion of CD11b2 DCs as a percentage of all DCs (E ) and an increased ratio of CD11b2 to CD11b1 DC (F ) compared with
WT at 72 hours after LPS exposures. (G) Allo mice transplanted with CCL22/2 donors have increased levels of the CD103 transcript in the lungs compared with
WT at 72 hours after LPS exposures. (H and I) Lung DCs were isolated fromWT, CCL22/2, or CCR22/2 LPS-exposed mice and cocultured with allogeneic T cells. The
resulting T cells were analyzed by flow cytometry, and intracellular IL-5 was measured. (H ) Representative flow diagrams show IL-51 T cells after coculture with DCs from
WT, CCL22/2, or CCR22/2 mice. (I) Allogeneic T cells cocultured with DCs from CCR22/2 mice, but not CCL22/2 mice, result in higher numbers of IL-51 T cells
compared with WT controls. Data represent the average 6 SEM. 1P , 0.05 comparing CCL22/2 group with WT. *P , 0.05 comparing CCR22/2 group with WT.
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literature showed divergent results and
demonstrated that CCR2 and CCL2 in fact
mediate AHR, mostly in models with
more acute allergen exposures (31–36). It
follows that the effects of CCR2 and
CCL2 on AHR depend on the context
under study and that the chronicity and
type of environmental exposures likely
play important roles.
In conclusion, our study
demonstrates that subacute iLPS-
potentiated pGVHD proceeds
independently of the CCL2–
CCR2 signaling axis. Despite reductions
in select populations of recruited lung
APCs, the overall immunological and
histopathological features of pGVHD
occur unabated in the setting of CCL2 or
CCR2 deficiency. Additionally, donor
CCL2 and CCR2 deficiency, likely
through the alteration of the lung APC
profile and up-regulation of IL-5 and IL-
13, lead to more AHR. Blockade of CCL2
or CCR2 in transplantation needs to be
further studied before speculating on its
clinical usefulness. n
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